HAS-BLED (Bleeding Risk on Anticoagulation)

About HAS-BLED (Bleeding Risk on Anticoagulation)

The HAS-BLED score, published by Pisters and colleagues in Chest in 2010, was developed to assess 1-year major bleeding risk in patients with atrial fibrillation who are receiving oral anticoagulation. It was derived from the Euro Heart Survey on AFib (3,978 patients) and validated in multiple cohorts. The score is widely recommended, by the European Society of Cardiology AFib guideline, the 2023 ACC/AHA/ACCP/HRS AFib guideline, and the Asia Pacific Heart Rhythm Society, as the preferred bleeding risk assessment tool because it identifies modifiable bleeding risk factors that can be addressed before anticoagulation is initiated.

What the calculator measures

The HAS-BLED score is an integer from 0 to 9 that estimates 1-year risk of major bleeding (intracranial hemorrhage, hospitalization for bleeding, hemoglobin drop >2 g/dL, and/or transfusion). Annual major bleeding risks are approximately 1-2% for a score of 0-1, 2-5% for a score of 2, 5-12% for a score of 3, and 12-20% for a score of 5 or higher.

How the formula works

The HAS-BLED acronym is the score:

• H. Hypertension (uncontrolled, systolic BP >160 mmHg) (1 point)
• A. Abnormal renal function (chronic dialysis, renal transplantation, or serum creatinine ≥2.0 mg/dL) (1 point)
• S. Abnormal liver function (chronic hepatic disease or biochemical evidence of significant hepatic derangement) (1 point)
• B. Prior major bleeding or predisposition to bleeding (1 point)
• L. Labile INRs (time in therapeutic range <60% in patients on warfarin) (1 point)
• E. Elderly (age ≥65) (1 point)
• D. Concurrent drugs (antiplatelet agents, NSAIDs) or excess alcohol (≥8 drinks/week) (1 point each, max 2 points)

The maximum score is 9, but most clinical scores cluster between 0 and 5.

Interpretation

The European Society of Cardiology and the 2023 ACC/AHA/ACCP/HRS AFib guideline emphasize that a high HAS-BLED score (≥3) is not a reason to withhold anticoagulation. Rather, it should prompt identification and correction of modifiable bleeding risk factors (uncontrolled hypertension, labile INRs, concurrent antiplatelet or NSAID use, excess alcohol). The stroke risk (CHA₂DS₂-VASc) and bleeding risk (HAS-BLED) should be assessed together; in most patients with elevated CHA₂DS₂-VASc, the stroke prevention benefit of anticoagulation outweighs the bleeding risk even when HAS-BLED is high, provided modifiable bleeding factors are addressed.

Clinical use

HAS-BLED is used at the time of AFib diagnosis (or at each clinical encounter) to assess bleeding risk before initiating anticoagulation. Modifiable risk factors should be addressed: control blood pressure (target <130/80 mmHg), discontinue antiplatelet agents unless there is a clear indication (e.g. recent stent), avoid NSAIDs, counsel on alcohol intake, and (for warfarin users) improve time in therapeutic range. Direct oral anticoagulants (DOACs) have lower bleeding risk than warfarin at equivalent efficacy, particularly for intracranial hemorrhage, and are preferred in patients with elevated HAS-BLED scores when anticoagulation is indicated.

Limitations

The HAS-BLED score has several limitations. First, the labile INR criterion applies only to warfarin users and is not applicable to patients on DOACs (where INR is not monitored); the score can be calculated without this criterion for DOAC patients, but the maximum score is then 8. Second, the score was derived in a European cohort and may perform differently in other populations. Third, the score does not capture all bleeding risk factors, it excludes thrombocytopenia, anemia, low body weight, frailty, and genetic factors affecting drug metabolism. Fourth, the score was derived in 2010, before DOACs became standard; modern bleeding rates with DOACs are lower than with warfarin at the same HAS-BLED score. Fifth, the score is categorical and does not incorporate the severity of each risk factor.

Comparison with ORBIT and ATRIA

Two alternative bleeding risk scores are ORBIT (O'Brien 2015) and ATRIA (Fang 2011). ORBIT was derived in a U.S. community cohort and includes age ≥75, anemia, prior bleeding, eGFR <60, and antiplatelet use; it has been validated in DOAC users. ATRIA includes anemia, severe renal disease, age ≥75, prior hemorrhage, and hypertension. The 2023 ACC/AHA/ACCP/HRS guideline lists all three scores as acceptable, with a slight preference for HAS-BLED because of its emphasis on modifiable risk factors. In practice, the choice of score often depends on local availability and clinician familiarity.

How to use the result

A HAS-BLED score of 3 indicates approximately 5-12% annual major bleeding risk. This is not a contraindication to anticoagulation; rather, it should prompt aggressive management of modifiable bleeding risk factors. For most patients with elevated CHA₂DS₂-VASc scores (≥2 in men or ≥3 in women), the stroke prevention benefit of anticoagulation outweighs the bleeding risk even with HAS-BLED ≥3, provided modifiable factors are addressed. DOACs are preferred over warfarin in these patients because of lower bleeding risk.